CMV-specific T-Cells for Treatment of CMV Infection after Hematopoietic Stem Cell Transplantation in a Pediatric Case: First Application in Turkey

Pediatrisk Bir Olguda HKHN Sonrası CMV Spesifik T Hücre Kullanımı: Türkiye’deki İlk Uygulama

To the Editor,

Cytomegalovirus (CMV) infection is still a major complication after allogeneic hematopoietic stem cell transplantation (HSCT) [1,2]. Unfortunately, prolonged antiviral treatment of CMV infection causes a delayed CMV-specific immune reconstitution. At this point, adoptive immunotherapy by CMV-specific T-cells can control CMV infection or provide immune reconstruction [3,4,5].

A 17-year-old boy with high-risk T-cell acute lymphoblastic leukemia underwent HSCT from one antigen-mismatched unrelated donor. He was conditioned with treosulfan, fludarabine, thiotepa, and rabbit anti-thymocyte globulin at 15 g/m² for 3 consecutive days (days -2 to 0). The patient also received cyclosporine A (CsA) divided into two doses: 3 mg/kg daily from day -1 to post-transplant days +20 and +30 intravenously then switched to approximately 6 mg/kg peroral daily (targeted blood concentration: 200-250 ng/mL with monitoring). CsA was tapered quickly and stopped in the third month of transplant due to renal failure. Methotrexate was administered on days +1 (10 mg/m²), +3 (8 mg/m²), and +6 (8 mg/m²). He achieved neutrophil engraftment on day +17 and thrombocyte engraftment on day +32. Full donor chimerness was observed in the first and third months. Lymphoid engraftment was achieved on day +75 but generally the absolute lymphocyte count was under 1500/mm³. He was CMV immunoglobulin G (IgG)-seropositive and CMV-DNA polymerase chain reaction (PCR) was negative before transplantation. Unfortunately, his donor was CMV IgG-seronegative. CMV infection (reactivation) occurred on day +19. Ganciclovir was started at 10 mg/kg/day and no response was obtained in 14 days. CMV drug resistance mutation was detected in the UL54 polymerase gene. Foscarnet was administered at 180 mg/kg/day on day +34. First, an increase of CD3+ lymphocytes was seen in the lymphocyte subtype analyses around the third month after the transplant. As a comorbidity, in spite of the fact that fluoroquinolone was administered until +30 day, BK virus infection developed in the patient and cidofovir was used at 5 mg/kg/week on days +52, +67, and +79. No response was achieved with the antiviral treatment and renal failure developed in the patient on day +82. All antivirals were stopped. According to the recent literature, the transplant council decided to use CMV-specific T-cells for the patient’s ongoing CMV infection. Informed consent was received from his family and the application was approved by the Ministry of Health’s Scientific Advisory Commission on Stem Cell Transplantation. In accordance with cGMP standards, peptide-specific T lymphocytes were isolated and amplified by a interferon-γ cytokine capture system using the fully automated CliniMACS Prodigy device at Acıbadem Labcell, İstanbul.
infusion doses of third-party CMV-specific T-cells were $2 \times 10^4$ cell/kg and $1 \times 10^4$ cell/kg in the 20th and 22nd weeks after transplantation, respectively. While the recommended dose of T-cells was $2 \times 10^6/m^2$ [6], we reduced the dose due to the risk of graft-versus-host disease (GvHD). The CMV-DNA PCR level was higher than $1 \times 10^5$ copies/mL before infusion and had decreased to $8 \times 10^4$ copies/mL on the 15th day after infusion. The patient had no immunosuppression at the time of T-cell infusion and did not develop GvHD after the infusion. In follow-up, CMV-DNA PCR increased to more than $3.5 \times 10^5$ copies/mL in the first month of the cell infusion and the sixth month after transplantation. In this period, CD3-CD16+56+ (natural killer) and CD3+CD8+ (T cytotoxic) lymphocyte subtypes were increased. Nevertheless, the patient developed respiratory distress and CMV infection was detected from the bronchoalveolar lavage sample, and the CMV DNA titer was 152,000 copies/mL. After losing partial response to CMV-specific T-cells, CMV pneumonia was proved and then leflunomide was tested, but there was no response. Finally, CMV-specific IgG was administered once weekly three times. This treatment managed to decrease the CMV DNA copies to under 20,000 copies/mL. The treatment process according to the course of CMV DNA titer is shown in Figure 1.

CMV reactivations/infections are life-threatening complications in the transplant setting, especially if the recipient and donor are CMV mismatches. From our experience with this case, CMV-specific T-cells can control viral replication to a certain extent, but not enough for permanent results. The answer may be CMV-specific IgG, which controlled CMV reactivation best in our case, and antivirals may be used in combination.

**Keywords:** Childhood, Hematopoietic stem cell transplant, CMV, Specific T-cell, Therapy

**Anahtar Sözcükler:** Çocuklu, Hematopoetik kök hücre nakli, CMV, Spesifik T hücre, Tedavi

**Informed Consent:** Informed consent was received from the family.

**Authorship Contributions**
Surgical and Medical Practices: S.C., E.T, B.A.A., E.O., C.B.; Design: E.T., C.B.; Data collection or Processing: S.C., E.T, B.A.A.; Analyses or Interpretation: E.O., C.B.; Literature Search: E.T., B.A.A.; Writing: E.T.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

**References**
1. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Löeffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916-3922.
2. Espigado I, de la Cruz-Vicente F, BenMarzouk-Hidalgo DJ, Gracia-Ahufinger I, Garcia-Lozano JR, Aguilar-Guisado M, Cisneros JM, Urbano-Ispizua A, Perez-Romero P. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation. Transpl Int 2014;27:1253-1262.
3. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-558.
4. Scheinberg P, Melenhorst JJ, Brenchley JM, Hill BJ, Hensel NF, Chattopadhyay PK, Roederer M, Picker LJ, Price DA, Barrett AJ, Douek DC. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood 2009;114:5071-5080.
Comparison of Different Culture Conditions for Mesenchymal Stem Cells from Human Umbilical Cord Wharton’s Jelly for Stem Cell Therapy

Kök Hücre Tedavisi için İnsan Kordon Kanı Wharton Jel’inden Üretilen Mezenkimal Kök Hücreler için Farklı Kültür Ortamlarının Karşılaştırılması

Yu Bao¹, Shumin Huang², Zhengyan Zhao²

¹Zhejiang University Faculty of Medicine, Children’s Hospital, Department of Nephrology, Zhejiang, China
²Zhejiang University Faculty of Medicine, Children’s Hospital, Clinic of Division of Child Health Care, Zhejiang, China

To the Editor,

Many recent studies have demonstrated that the umbilical cord is an excellent source of mesenchymal stem cells (MSCs) [1,2,3]. However, in order to use human umbilical cord Wharton’s jelly-derived mesenchymal stem cells (hUC-MSCs) in clinical therapy, a suitable culture procedure for good manufacturing practice-compliant production is mandatory. Nutritional deficiency is the major pathophysiological situation in an ischemic microenvironment in the clinic [4]. Thus, the development of serum-free culture systems is needed [5]. Furthermore, hypoxia is common in vivo in mammals [6]. The average oxygen tension falls to 1% in some cases of pathological ischemia, including fracture hematoma, and in cases of myocardial ischemia [7]. Hence, the investigation of biological characteristics of hUC-MSCs exposed to hypoxic and/or serum-free conditions is of great interest.

In our study, we conducted parallel assays by using four cell groups. For the hypoxic controls, cells from group A (n=10) and group B (n=10) were exposed to 5% CO₂ and 94% N₂ in an airtight modular incubator chamber (Billups-Rothenberg Inc., Del Mar, CA, USA). The final oxygen tension was 1%-3% as measured by an oximeter (Oxybaby M+, Witt Technology, Solza, Italy). For the normoxic controls, cells from group C (n=10) and group D (n=10) were placed in an incubator at 37 °C, 5% CO₂, and 21% O₂. Cells from group A and group C were expanded in a mixture of Dulbecco’s modified Eagle’s medium and nutrient mixture F-12 (GIBCO, USA) supplemented with 10% fetal bovine serum (GIBCO, USA). Cells from group B and group D were expanded in StemPRO MSC serum-free medium (StemRD, USA). Flow cytometric analysis, differentiation potential, proliferative activities, cell cycle analysis, and apoptosis analysis of these four cell populations were evaluated. We repeated all these experiments 3 times.

Flow cytometry analysis of MSC-specific surface marker expression showed that hUC-MSCs cultured under four experimental conditions for six passages were positive for CD44, CD73, CD90, CD105, and HLA-ABC (BD Pharmingen, USA) and negative for CD34, CD45, CD14, and HLA-DR (BD Pharmingen, USA); no significant differences were detected between the four cell populations (Figure 1). This finding indicates that culturing cells under hypoxic and/or serum-free conditions did not induce significant variations in the typical MSC marker expression profile. hUC-